Medicine and HealthNature Medicine
MYC targeting by OMO-103 in solid tumors: a phase 1 trial
E. Garralda, M. Beaulieu, et al.
This phase 1 study explores the safety and tolerability of OMO-103, a MYC inhibitor, in patients with advanced solid tumors. The findings revealed promising insights, with several patients maintaining stable disease after treatment. This research was conducted by a team of experts including Elena Garralda and Marie-Eve Beaulieu.
Related Publications
Explore these studies to deepen your understanding
Adjacent work that informs or extends this paper's methodology and findings.
Medicine and Health
Locoregional delivery of IL-13Rx2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial
C. E. Brown, J. C. Hibbard, et al.
Medicine and Health
PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial
T. B. Dorff, M. S. Blanchard, et al.
Medicine and Health
Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trial
P. Eijsvogel, P. Misra, et al.
Medicine and Health
Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial
J. Rodón, S. Damian, et al.
